EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-1335

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience ; volume:147 ; number:8 ; day:18 ; month:5 ; year:2021 ; pages:2301-2307 ; date:8.2021
Journal of cancer research and clinical oncology ; 147, Heft 8 (18.5.2021), 2301-2307, 8.2021

Creator: Ianza, Anna
Chicco, A. Di
Biagi, C.
Giudici, F.
Dicorato, A.
Guglielmi, A.
Variola, F.
Tomasi, S.
Roviello, G.
Generali, D.
Zanconati, F.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00432-021-03658-8

URN: urn:nbn:de:101:1-2021101010562358864938

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ianza, Anna
Chicco, A. Di
Biagi, C.
Giudici, F.
Dicorato, A.
Guglielmi, A.
Variola, F.
Tomasi, S.
Roviello, G.
Generali, D.
Zanconati, F.
SpringerLink (Online service)

Other Objects (12)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Related objects

Reset password